NeoGenomics Debuts RaDaR ST Assay for Residual Disease in Breast, Lung, Colorectal Tumors
NeoGenomics has launched RaDaR ST, a next-generation sequencing-based molecular residual disease assay now commercially available for multiple solid tumor types including breast, lung and colorectal cancers. This test provides ultra-sensitive circulating tumor DNA detection post-treatment, expanding the company's oncology diagnostics suite and supporting earlier relapse monitoring.
1. Product Launch
On February 25, NeoGenomics introduced RaDaR ST, its new molecular residual disease assay designed for solid tumors. The launch marks the company's first ctDNA-based MRD test tailored to breast, lung and colorectal cancers.
2. Test Features
RaDaR ST employs next-generation sequencing to detect circulating tumor DNA with ultra-sensitive resolution post-treatment. The assay’s expanded coverage enables monitoring of residual disease across a broad range of solid tumor types.
3. Business Impact
The rollout of RaDaR ST broadens NeoGenomics’ oncology diagnostics portfolio and could drive new revenue streams. Early detection of relapse through MRD monitoring may strengthen partnerships with oncology centers and biopharma clients.